

Arthur R Bradwell

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3143378/publications.pdf>

Version: 2024-02-01

21
papers

1,486
citations

1040056

9
h-index

794594

19
g-index

21
all docs

21
docs citations

21
times ranked

1280
citing authors

#	ARTICLE	IF	CITATIONS
1	Postexercise urinary alpha-1 acid glycoprotein is not dependent on hypoxia. <i>Journal of Applied Physiology</i> , 2022, 132, 261-269.	2.5	1
2	Effect of losartan on performance and physiological responses to exercise at high altitude (5035 m). <i>BMJ Open Sport and Exercise Medicine</i> , 2021, 7, e000982.	2.9	2
3	Losartan Has No Effect on High Altitude Diuresis or Acute Mountain Sickness in Well-Acclimatizing Individuals. <i>High Altitude Medicine and Biology</i> , 2021, 22, 96-101.	0.9	2
4	Long-term remission of disseminated parathyroid cancer following immunotherapy. <i>Endocrine</i> , 2020, 67, 204-208.	2.3	15
5	Hypoxia is not the primary mechanism contributing to exercise-induced proteinuria. <i>BMJ Open Sport and Exercise Medicine</i> , 2020, 6, e000662.	2.9	3
6	RE: Normal Serum Free Light Chain Concentrations in Femoroacetabular Impingement—Evidence Against a Systemic Inflammatory Response. <i>Journal of Orthopaedic Research</i> , 2019, 37, 2623-2624.	2.3	0
7	No Evidence of Systemic Inflammation in Symptomatic Patients With Femoroacetabular Impingement. <i>Journal of Orthopaedic Research</i> , 2019, 37, 2189-2196.	2.3	3
8	High cutoff versus high-flux haemodialysis for myeloma cast nephropathy in patients receiving bortezomib-based chemotherapy (EuLITE): a phase 2 randomised controlled trial. <i>Lancet Haematology</i> , 2019, 6, e217-e228.	4.6	80
9	Acetazolamide reduces exercise capacity following a 5-day ascent to 4559 m in a randomised study. <i>BMJ Open Sport and Exercise Medicine</i> , 2018, 4, e000302.	2.9	11
10	Urinary Alpha-1-Acid Glycoprotein Is a Sensitive Marker of Glomerular Protein Leakage at Altitude. <i>High Altitude Medicine and Biology</i> , 2018, 19, 295-298.	0.9	9
11	The Effect of Acetazolamide on Saccadic Latency at 3459 Meters. <i>Wilderness and Environmental Medicine</i> , 2015, 26, 72-77.	0.9	5
12	Exercise Limitation of Acetazolamide at Altitude (3459 m). <i>Wilderness and Environmental Medicine</i> , 2014, 25, 272-277.	0.9	29
13	Commentary. <i>Clinical Chemistry</i> , 2011, 57, 1648-1649.	3.2	0
14	Serum Heavy/Light Chain and Free Light Chain Measurements Provide Prognostic Information, Allow Creation of a Prognostic Model and Identify Clonal Changes (clonal tiding) Through the Course of Multiple Myeloma (MM). <i>Blood</i> , 2011, 118, 2883-2883.	1.4	4
15	Assessment of Monoclonal Gammopathies by Nephelometric Measurement of Individual Immunoglobulin κ/λ Ratios. <i>Clinical Chemistry</i> , 2009, 55, 1646-1655.	3.2	121
16	Heavy/Light Chain Specific Immunoglobulin Ratios at Presentation Are Prognostic for Progression Free Survival in the IFM 2005-01 Myeloma Trial. <i>Blood</i> , 2009, 114, 1818-1818.	1.4	10
17	Abnormal Serum IgA Kappa / IgA Lambda Ratios at Maximum Response Predict Poor Progression Free Survival in Myeloma Patients. <i>Blood</i> , 2009, 114, 4879-4879.	1.4	1
18	Intermediate Dose Intravenous Melphalan and Dexamethasone Treatment in 144 Patients with Systemic AL Amyloidosis. <i>Blood</i> , 2004, 104, 755-755.	1.4	7

#	ARTICLE	IF	CITATIONS
19	Serum test for assessment of patients with Bence Jones myeloma. <i>Lancet</i> , The, 2003, 361, 489-491.	13.7	238
20	Serum Reference Intervals and Diagnostic Ranges for Free κ and Free λ Immunoglobulin Light Chains: Relative Sensitivity for Detection of Monoclonal Light Chains. <i>Clinical Chemistry</i> , 2002, 48, 1437-1444.	3.2	577
21	Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. <i>Blood</i> , 2001, 97, 2900-2902.	1.4	368